The trial, ACT-OA, is a phase II, randomized, double-blind, placebo-controlled trial including 90 patients. It aims to evaluate the efficacy and safety of Cytori Cell Therapy — the company’s autologous adipose derived therapy.
The patient was treated by Peter Hanson, MD, medical director of orthopedic surgery at Sharp Grossmont Hospital in San Diego.
More articles on devices:
Medtronic’s VERTEX Reconstruction System receives FDA approval for expanded indications
Sonoma Orthopedic Products receives FDA clearance for FibuLock Nail
Argus raises Integra Lifesciences’ price target to $61
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
